Oncolytic Immunotherapy

Morgan L Hennessy; Praveen K Bommareddy; Genevieve Boland; Howard L Kaufman

doi:10.1016/j.soc.2019.02.007

Oncolytic Immunotherapy

Surg Oncol Clin N Am. 2019 Jul;28(3):419-430. doi: 10.1016/j.soc.2019.02.007. Epub 2019 Apr 5.

Authors

Morgan L Hennessy¹, Praveen K Bommareddy², Genevieve Boland¹, Howard L Kaufman³

Affiliations

¹ Division of Surgical Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 7B, Boston, MA 02114, USA.
² School of Graduate Studies, Graduate School of Biomedical Sciences, Rutgers University, 195 Little Albany Street, New Brunswick, NJ 08901, USA.
³ Division of Surgical Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 7B, Boston, MA 02114, USA; Replimune, Inc., Woburn, MA, USA. Electronic address: HLKaufman@mgh.harvard.edu.

PMID: 31079797
DOI: 10.1016/j.soc.2019.02.007

Abstract

Oncolytic viruses are naturally occurring, or genetically engineered viruses that can be administered via intralesional injections or intravenously to induce cell death in tumor cells and activate antitumor immune responses. This review summarizes several oncolytic viruses in preclinical and clinical trials, describes challenges in clinical implementation, and important areas of future investigation.

Keywords: Cancer; Immunogenic cell death; Immunotherapy; Intratumoral; Oncolytic virus; Treatment.

Publication types

Review

MeSH terms

Animals
Humans
Immunotherapy / methods*
Neoplasms / genetics
Neoplasms / immunology
Neoplasms / therapy*
Oncolytic Virotherapy / methods*
Oncolytic Viruses / genetics
Oncolytic Viruses / immunology*